Issues of inflammatory bowel disease management in primary care

PHD M. Brynza, аs. K. Uvarova

V. N. Karazin Kharkiv National University

Іnflammatory bowel diseases are among various chronic processes, which, in the case of inadequate diagnosis and irrational treatment, eventually lead to highly unfavorable consequences. Thus, the timely establishment of the diagnosis, as well as the prescription of effective therapy and the subsequent careful follow-up of patients with inflammatory bowel diseases is the key to prolongation of the patients’ wellbeing and prevention of the occurrence of severe complications. Due to the possible increase in the prevalence of these pathologies in the future, close and effective cooperation between specialists and primary care physicians is extremely important nowadays. Unfortunately, there are currently no tools that can be used by primary care physicians to improve the routing of patients with inflammatory bowel disease. However, close and clear communication between primary and secondary healthcare specialists should become an integral part of health care systems, including that in our country.

Key words: inflammatory bowel disease, primary healthcare, disease management.

Download.PDF (ukr)


1. Бринза, М.С., Уварова, К.Г. Питання ведення запальних захворювань кишечника на етапі первинної ланки надання медичної допомоги // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2021. – №1. – С. 109-115. doi: 10.15407/internalmed2021.01.109

2. Brynza MS, Uvarova KG. [Issues of inflammatory bowel disease management in primary care]. Shidnoevr. z. vnutr. simejnoi med. 2021;1:109-115. Ukrainian. doi: 10.15407/internalmed2021.01.109


1. Lamb C, Kennedy N, Raine T. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:106.

2. Hicks A, Hamlin P, Selinger C. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflammatory Intestinal Diseases. 2020;5(4):191-199.

3. Tan M, Holloway R, Lange K, Andrews J. General practitioners’ knowledge of and attitudes to inflammatory bowel disease. Internal Medicine Journal. 2012;42(7):801-807.

4. Bennett A, Munkholm P, Andrews J. Tools for primary care management of inflammatory bowel disease: Do they exist?. World Journal of Gastroenterology. 2015;21(15):4457-4465.

5. Aljebreen A, Alharbi O, Azzam N. Clinical epidemiology and phenotypic characteristics of Crohn’s disease in the central region of Saudi Arabia. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2014;20 (3):162.

6. Al-Qabandi W, Hamadi K, Al-Ruwayeh A, Buhamrah E, Al-Osaimi S, Madda J. Inflammatory bowel disease in children, an evolving problem in Kuwait. Saudi Journal of Gastroenterology. 2011;17(5):323.

7. Dahlhamer J, Zammitti E, Ward B, Wheaton A, Croft J. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years – United States, 2015. MMWR. Morbidity and Mortality Weekly Report. 2016;65(42):1166-1169.

8. Ouyang G, Pan G, Liu Q, Wu Y, Liu Z, Lu W, Li S, Zhou Z, Wen Y. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. BMC Medicine. 2020;18(1):.

9. Stepanov YuM, Skyrda YuM., Petyshko OP. Khronichni zapalni zakhvoriuvannia kyshechnyka: osoblyvosti epidemiolohii v Ukraini. Hastroenterolohiia. 2017. t. 51; 2:97-105. Ukrainian

10. Schroeder K, Tremaine W, Ilstrup D. Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. New England Journal of Medicine. 1987;317(26):1625-1629.

11. Paine E. Colonoscopic evaluation in ulcerative colitis. Gastroenterology Report. 2014;2(3):161-168.

12. Costrini N. Clearing of the Clouds in Inflammatory Bowel Disease Management. Digestive Diseases and Sciences. 2020;65(12):3411-3417.

13. Dulai P, Boland B, Singh S. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease. Gastroenterology. 2018;155:687-695.

14. Lichtenstein G, Loftus E, Isaacs K, Regueiro M, Gerson L, Sands B. Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults. American Journal of Gastroenterology. 2018;113(7):1101.

15. Vermeire S. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006;55(3):426-431.

16. Vavricka S, Spigaglia S, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger C, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer A. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases. 2012;18(3):496-505.

17. Gallinger Z, Ungaro R, Colombel J, Sandler R, Chen W. P030 DELAYED DIAGNOSIS OF CROHN’S DISEASE IS COMMON AND ASSOCIATED WITH AN INCREASED RISK OF DISEASE COMPLICATIONS. Gastroenterology. 2019;156(3):14-15.

18. Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, Giannarelli D, Massari A, Monterubbianesi R, Lenti M, Corazza G, Kohn A. The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. Journal of Crohn’s and Colitis. 2017;11(8):975-980.

19. Mao R, Xiao Y, Gao X, Chen B, He Y, Yang L, Hu P, Chen M. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflammatory Bowel Diseases. 2012;18(10):1894-1899.

20. Guideline D. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. National Institute for Health and Care Excellence. 2013. Available from: https://www.nice. (Accessed 03 Feb 2021)

21. Turvill J, Turnock D, Holmes H, Jones A, Mclaughlan E, Hilton V, Marriott S. Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway. Frontline Gastroenterology. 2018;9(4):285-294.

22. El Mouzan M, AlSaleem B, Hasosah M, Al-Hussaini A, Al Anazi A, Saadah O, Al Sarkhy A, Al Mofarreh M, Assiri A. Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia. Saudi Journal of Gastroenterology. 2019;25(4):257.

23. Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein C. The Manitoba Inflammatory Bowel Disease Cohort Study: Prolonged Symptoms Before Diagnosis-How Much Is Irritable Bowel Syndrome?. Clinical Gastroenterology and Hepatology. 2006;4(5):614-620.

24. Mosli M, Bamarhul M, Alharbi A. Screening irritable bowel syndrome patients for symptoms predictive of Crohn’s disease using the red flag score. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017;23(4):229.

25. Mosli M, Alharbi R, Almahmudi F, Makhdoom Y. Knowledge and attitudes of primary healthcare physicians toward the diagnosis and management of inflammatory bowel disease following an educational intervention: A comparative analysis. Saudi Journal of Gastroenterology. 2019;25(5):277.

26. NICE Guideline Updates Team (UK). Ulcerative colitis: management. London: National Institute for Health and Care Excellence (UK); 2019 May. PMID: 31356033. Available from: https:// (Accessed 03 Feb 2021)

27. Alexakis C, Oliver C, Hockney E, Amoyel A, Grayson C, Pollok R, Saxena S. PWE-010 Monitoring IBD Medications in Primary Care: Audit of Practice in South West London. Gut. 2016;65:142.

28. Aldulaimi D, Farmer D, Prasher H, Jazrawi R. PWE-011 Is Ulcerative Colitis (UC) Managed Adequately in Primary Care?. Gut. 2016;65:A142.

29. Goel A, Johnson T, Limdi J. Vaccinating Patients With IBD: Still to Begin, At the Beginning. American Journal of Gastroenterology. 2014;109:S517.

30. Niv Y, Dickman R, Levi Z, Neumann G, Ehrlich D, Bitterman H, Dreiher J, Cohen A, Comaneshter D, Halpern E. Establishing an integrated gastroenterology service between a medical center and the community. World Journal of Gastroenterology. 2015;21(7):2152-2158.

31. Price T, Lithgow K, Johnson M. The UK’s first internet based remote management system for monitoring stable IBD patients in the community, IBD SSHAMP (supported self help and management programme). United European Gastroenterology Journal. 2013;1:52-53.

32. Casellas F, Marín-Jiménez I, Borruel N, Riestra S. Colitis ulcerosa en remisión: mejora de la adhesión terapéutica desde una perspectiva multidisciplinar. Enfermedad Inflamatoria Intestinal al Día. 2016;15(2):37-43.

33. Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2017;23(2):318-324.

34. Ruiz-Cuesta P, González-Alayón C, Jurado-García J, Iglesias-Flores E, Barranco-Quintana J, García-García L, Salgueiro-Rodríguez I, Benitez-Cantero J, García-Sánchez V. Adherence to a predefined vaccination program in patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition). 2016;39(6):385-392.

35. Christensen K, Steenholdt C, Brynskov J, Buhl S, Thomsen O, Ainsworth M. Tu1845 Systematic Information to Healthcare Professionals About Vaccination Guidelines Markedly Improves Adherence in Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy. Gastroenterology. 2015;148(4):S-918.

36. Teich N, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, Schiefke I. Vaccination Coverage in Immunosuppressed Patients. Deutsches Aerzteblatt Online. 2011;:.

37. Abdallah J, Anna K, Hassan T, Jain A. P-049 Vaccination Rates in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2013;19:46.

38. Christensen B, Headon B, Gibson P. Inflammatory bowel disease: the GP’s role in shared care of patients. Med Today. 2013;14:16-28.

39. Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup J, Salupere R, Nielsen K, Olsen J, Manninen P, Collin P, Tsianos E, Katsanos K, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D’Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros L, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos P, Langholz E, Munkholm P. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2013;63(4):588-597.

40. Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Avnstrøm S, Vinding K, Olsen J, Nielsen K, Katsanos K, Tsianos E, Lakatos L, Schwartz D, Odes S, Lupinacci G, De Padova A, Jonaitis L, Kupcinskas L, Turcan S, Tighineanu O, Mihu I, Barros L, Magro F, Lazar D, Goldis A, Fernandez A, Hernandez V, Niewiadomski O, Bell S, Langholz E, Munkholm P, Lakatos P. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. Journal of Crohn’s and Colitis. 2014;8(11):1506-1515.

41. Sossai P, Filippetti F, Muselmani AA, Catalini G. Inflammatory bowel diseases and the general practitioner’s role in a region of Central Italy. Clin Exp Gastroenterol. 2010;3:27-31.